0
  • All Categories
  • UK News
  • Europe
  • Global
  • R & D
  • Sales & Marketing
  • Manufacturing
  • Digital
  • Industry Insights
  • Appointments
  • Interviews
  • Features
  • Industry Facts
article-item
FDA approves Pfizer’s Beqvez for treatment of haemophilia B

Pfizer has announced that the FDA has approved Beqvez (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate-to-severe haemophilia B.

4 June 2024Global
article-item
Sanofi, Formation Bio and OpenAI announce new AI collaboration

Sanofi, Formation Bio and OpenAI have announced that they have entered into a collaboration with the aim of building AI-powered software to accelerate the drug development process and bring new drugs to market and to patients more efficiently.

4 June 2024R & D
article-item
PharmaTimes

Www.pharmatimes.com/croy

4 June 2024
article-item
Contents

Welcome to the June 2024 issue of Pharmafocus!

4 June 2024
article-item
PharmaRole

Pharmarole.com

4 June 2024
article-item
AstraZeneca invests $1.5bn to build ADC facility in Singapore

AstraZeneca has announced that it intends to build a $1.5bn manufacturing facility in Singapore, Singapore, for antibody drug conjugates (ADCs), with the aim of enhancing its global supply of its ADC portfolio.

4 June 2024Manufacturing
article-item
GSK invests £45m with Fleming Initiative to combat AMR

GSK has announced that it has pledged £45m to the Fleming Initiative, becoming the first founding partner of the innovative and collaborative approach to tackle antimicrobial resistance (AMR).

4 June 2024R & D
article-item
Eli Lilly increases investment for manufacturing to $9bn at new Indiana site

Eli Lilly has announced that it has more than doubled its investment at its Lebanon, Indiana, US manufacturing site with a new $5.3bn investment, increasing its investment at this site to $9bn from its original $3.7bn.

4 June 2024Manufacturing
article-item
Comment

Considering lgbtq+ healthcare and pride month

4 June 2024
article-item
SAMEDAN

Www.samedanltd.com

4 June 2024
article-item
Boehringer Ingelheim & OSE Immunotherapeutics to collaborate on cancer & metabolic disease treatment

OSE Immunotherapeutics and Boehringer Ingelheim have announced a major expansion of their existing partnership.

4 June 2024R & D
article-item
J&J’s Tremfya meets endpoints in UC study

Johnson & Johnson has announced the first data from its phase 3 QUASAR maintenance study, which assessed Tremfya (guselkumab) as a treatment for patients with moderately-to-severely active ulcerative colitis (UC).

4 June 2024R & D